



7th DZHK Retreat

Personalized Cardiovascular Medicine

12-14 September 2019

PROGRAM

PROGRAM



Thursday, 12 September 2019

Opening

3:30 PM - 05:00 PM

03:30-04:00 Welcome coffee

04:00-04:15 Thomas Sommer, Tanja Zeller, Holger Gerhardt Welcome

04:15-05:00 Thomas Eschenhagen, Hamburg
DZHK - State of affairs

Keynote

05:00 PM-05:45 PM

Chair: Lars Maegdefessel

05:00-05:45 Calum MacRae, Harvard Medical School

Integrative high-throughput modeling to understand the mechanisms of atrial


fibrillation

05:45 Group photo

06:00-07:30 Dinner

Young DZHK poster session I 07:30 PM - 09:00 PM

09:00 Get together





Friday, 13 September 2019

1st Session: Personalized cardiovascular medicine I

(to be continued on day 3)

08:30 AM - 10:30 AM

Chairs: Djawid Hashemi, Tobias Petzold

08:30-08:50 Stephan B. Felix, Greifswald

Immunoadsorption in patients with dilated cardiomyopathy

09:00-09:20 Laura Zelarayan, Göttingen

CRISPR-mediated activation of endogenous gene expression to restore

homeostasis

09:30-09:50 Maximilian Emmert, Berlin

Next generation regenerative implants to repair the diseased heart

10:00 - 10:35 Friedrich Luft, Berlin

Critical view on personalized medicine

10:45 - 11:30 Coffee break

2nd Session: Highlight talks from the Young DZHK Retreat

11:30 AM - 12:30 PM

Chairs: Nadya Al-Wakeel-Marquard,

Tobias Jakobi

Talks will be selected during the Young DZHK Retreat which takes places prior to the main retreat.

12:30-02:30 Lunch break

Keynote

02:30 PM - 03:15 PM

Chair: George Kararigas

02:30-03:15 Leslie Leinwand, University of Colorado

Pathogenesis and treatment of genetic cardiomyopathies

03:15-03:45 Coffee break

Team events

04:00 PM - 06:00 PM

04:00-06:00 Team events: Dragon boat or guided city tour

06:15-07:30 Dinner

Young DZHK poster session II 07:30 PM - 09:00 PM

Saturday, 14 September 2019



3rd Session: DZHK papers of the months 2018 - flash talks

08:15 AM - 09:15 AM

Chairs: Nuno Camboa, Eileen Moritz

- 01 Jiong Hu, Frankfurt
 Inhibition of soluble epoxide hydrolase prevents
 diabetic retinopathy
- O2 Eike Nagel, Frankfurt Native T1 and ECV of noninfarcted myocardium and outcome in patients with coronary artery disease
- O3 Anne-Clemence Vion, Nantes
 Primary cilia sensitize endothelial cells to BMP
 and prevent excessive vascular regression
- 04 Jan Christoph, Göttingen Electromechanical vortex filaments during cardiac fibrillation
- Uars MaegdefesselH19 induces abdominal aortic aneurysm development and progression
- 06 Richard Schell, Heidelberg Inflammation leads through PGE/EP3 signaling to HDAC5/MEF2-dependent transcription in cardiac myocytes
- 07 Carlos Silvestre-Roig, Munich Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis
- O8 Andreas Daiber, Mainz Crucial role for Nox2 and sleep deprivation in aircraft noise-induced vascular and cerebral oxidative stress, inflammation, and gene regulation
- O9 Friedrich Köhler, Berlin Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial
- 10 Alexander Meyer, Berlin Machine learning for real-time prediction of complications in critical care: a retrospective study

- 11 Belal Mohamed, Göttingen Sarcoplasmic reticulum calcium leak contributes to arrhythmia but not to heart failure progression
- 12 Hendrik Bartolomaeus, Berlin The short-chain fatty acid propionate protects from hypertensive cardiovascular damage

09:15-09:45 Coffee break

4th Session: Flash talks on selected abstracts

09:45 PM - 10:25 PM

Chairs: Norman Liaw, Anca Remes

09:45-09:50 Lukas Cyganek, Göttingen

Exploring LZTR1-associated Noonan Syndrome in patient-specific and CRISPR corrected iPSC-derived cardiomyocytes

09:55 - 10:00 Jirko Kühnisch, Berlin

Genetic modelling of PRDM16 associated cardiomyopathy in mice leads to diverse subtypes of heart failure

10:05 – 10:10 Farbod Sedaghat-Hamedani, Heidelberg First results of TranslatiOnal Registry for CardiomyopatHies (TORCH)

10:15-10:20 Mariya Kucherenko, Berlin

Pulmonary arterial stiffening in pulmonary hypertension due to left heart disease

10:25 - 11:00 Coffee break & checking-out of rooms

5th Session: Personalized cardiovascular medicine II

11:00 AM - 12:30 PM

Chairs: Michelle Collins, Katharina Scherschel

11:00 – 11:15 Stefanie Dimmeler, Frankfurt
RNA Therapeutics for Cardiovascular
Disease

11:20-11:35 Anne Dueck, Munich

Single cell transcriptomics of coding and non-coding RNA to study cardiovascular disease

- 11:40-11:55 Timon Seeger, Heidelberg iPSC for modeling cardiac disease
- 12:00 12:15 Arne Hansen, Hamburg

 Phospholamban Arg14del hiPSC
 disease modelling in the dish
 - 12:30 Gerd Hasenfuss and Johannes Backs Closing remarks
 - 12:40 End of the meeting / take a packed lunch from the lobby
 - 01:00 Bus departures

KEYNOTE SPEAKERS



Leslie Leinwand

Leslie Leinwand, PhD is a Molecular, Cellular, and Developmental Biology (MCDB) Distinguished Professor and the Chief Scientific Officer of the BioFrontiers Institute at the University of Colorado Boulder. She received her Bachelor's degree from Cornell University, her PhD from

Yale University and did post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado in 1995. She has founded several companies, most recently MyoKardia, Inc. The interests of Dr. Leinwand's laboratory are the genetics and molecular physiology of inherited diseases of the heart and how gender and diet modify the heart.



Calum MacRae

Calum MacRae, MD, PhD, is the Vice Chair for Scientific Innovation in the Department of Medicine at Brigham and Women's Hospital in Boston, an Associate Professor of Medicine at Harvard Medical School, a Principal Faculty Member at the Harvard Stem Cell Institute, and


an Associate Member at the Broad Institute of Harvard and MIT. MacRae works on the human genetics of cardiac and vascular disease, cardiovascular developmental biology, and drug discovery. He has a longstanding interest in the incorporation of genomics and other large-scale datasets into clinical practice, systematic approaches to the discovery of new translatable phenotypes, and the role of disruptive innovation in refashioning the translational interface. His major clinical focus is the Cardiovascular Clinical Genetics Center, he co-directs the Genomic Medicine Program and he also has established a Next Gen Phenotyping Center at Brigham and Women's Hospital.

NOTES

FLOOR PLAN

ground floor

- STC = Seminar & Training Center
- ECC = Executive Conference Center
- PBA = Plenary & Banquet Area
- Foyers



Committee and working group meetings

Thursday, 12 September	Time	Room
Meeting of the DZHK study Pls	08:00 AM-10:00 AM	3-4
Clinical Staff/Study	08:00 AM-12:00 PM	1-2
Coordinators		
RCC	10:00 ам-11:30 ам	7-8
General Assembly	12:00 рм-02:30 рм	7-8
WGCR	01:00 рм-03:30 рм	1-2
DZHK Partner Site Managers	01:00 рм-03:30 рм	4
DZHK Professors	01:30 рм-03:30 рм	SP*
ECG working group	06:30 рм-07:30 рм	1-2
Al and Imaging project groups	07:30 рм-08:00 рм	1-2
Friday, 13 September		
OMICs	07:00 ам-08:30 ам	3
DZHK Evaluation	01:00 рм-02:30 рм	3
Use & Access Committee	01:30 рм-02:30 рм	SP*
*Seminarraum Spree		

7th DZHK Retreat

Date: 12–14 September 2019

Venue: Seminaris SeeHotel Potsdam

An der Pirschheide 40 14471 Potsdam

WiFi access: User name: SEMINARIS

Password: POTSDAM

To submit questions during the sessions you can

join at: www.slido.com

Event code: DZHK7

Contact: Annett Grützmacher

Retreat Mobile: +49 (0) 176 266 937 42

E-mail: retreat@dzhk.de https://retreat2019.dzhk.de/